Sagimet is a clinical-stage biotech narrowing its strategy around denifanstat in acne: after securing FDA clearance to proceed, it is moving toward a U.S. registrational Phase 3 trial, while deprioritizing MASH unless it finds non-dilutive funding. That U.S. Phase 3 plan was already publicly telegraphed for the second half of 2026, and the company had said in August that screening was on track for the fourth quarter, so the direction of travel was known.
The new information is the durability, not the existence of efficacy. Sagimet’s partner had already reported positive topline open-label-extension data earlier in 2026; this filing supplies the full 52-week readout and confirms continued improvement after the original 12-week randomized study. The OLE included 240 patients, with efficacy assessed from the ASC40-303 baseline. 〔0〕
| 52-week OLE result | Total cohort | Filing reference |
|---|---|---|
| IGA treatment success | 56.7% | (Phase 3 Open-Label Extension Results) |
| Total-lesion change from baseline | -71.8% | (Phase 3 Open-Label Extension Results) |
| Inflammatory-lesion change from baseline | -76.9% | (Phase 3 Open-Label Extension Results) |
| Non-inflammatory-lesion change from baseline | -66.9% | (Phase 3 Open-Label Extension Results) |
| Treatment-related dry skin | 7.1% | (Phase 3 Open-Label Extension Results) |
| Treatment-related dry eye | 5.9% | (Phase 3 Open-Label Extension Results) |
The result clears the trial’s practical bar, but it is not a fresh placebo-controlled win. The open-label design and secondary efficacy endpoints make this primarily a long-term support package for the U.S. program, not a new controlled proof-of-concept event. Still, the magnitude of sustained lesion reduction and the similar response rates for prior placebo patients versus prior denifanstat patients strengthen the case that benefit can continue beyond 12 weeks. 〔1〕
Long-term tolerability remains supportive rather than decisive. Through 52 weeks, the filing reports no drug-related serious adverse events and no permanent discontinuations caused by adverse events; the main recurring treatment-related issues were dry skin and dry eye. 〔2〕 That reduces one important development concern, but the decisive test remains whether the U.S. randomized AURORA study reproduces the efficacy signal in a different population and trial setting.
The ATM termination is a secondary capital-market housekeeping item, not a new financing. Sagimet will not sell shares under the existing prospectus supplement unless it files a replacement prospectus or registration statement, so this removes near-term use of that issuance channel but does not change the separate sales agreement. 〔3〕
Bottom line: The filing upgrades denifanstat’s acne story from promising short-term efficacy to credible 52-week durability and tolerability. It matters because it supports the imminent U.S. Phase 3 launch, although the core clinical risk has shifted to reproducing these results in the controlled AURORA trial rather than proving that the drug can work long term in China’s open-label extension.
Read the original 8-K on SEC EDGAR ↗